FibroGen vs. Hangzhou Andao: Indolizine Patent Dispute Dismissed With Prejudice
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | FibroGen, Inc. v. Hangzhou Andao Pharmaceutical, Ltd. et al. |
| Case Number | 3:22-cv-07148 (N.D. Cal.) |
| Court | U.S. District Court for the Northern District of California |
| Duration | Nov 2022 – Apr 2024 515 days |
| Outcome | Defendant Win — Dismissed with Prejudice |
| Patents at Issue | |
| Accused Products | Indolizine Derivatives & Medical Applications |
Case Overview
The Parties
⚖️ Plaintiff
A San Francisco-based biopharmaceutical company known for its work in fibrosis and anemia therapeutics, maintaining a substantial patent portfolio in small-molecule chemistry.
🛡️ Defendant
A China-based pharmaceutical developer, along with co-defendants Kind Pharmaceuticals, LLC, Dr. Dong Liu, and Dr. Shaojiang Deng, suggesting allegations tied to research personnel or parallel commercialization efforts.
The Patent at Issue
This litigation centered on **U.S. Patent No. US11021478B2** (Application No. US16/611838), directed to indolizine derivatives and their application in medicine. Indolizine-based compounds are a significant area of pharmaceutical innovation, with applications in oncology, inflammation, and other therapeutic categories.
- • US11021478B2 — Indolizine derivatives and medical applications
Developing novel chemical compounds?
Check if your small-molecule structures might infringe existing patents before synthesis or trials.
The Verdict & Legal Analysis
Outcome
On **April 12, 2024**, the court entered an order pursuant to a **Joint Stipulation of Dismissal**, with all claims by FibroGen, Inc. and all counterclaims by the defendants dismissed **with prejudice**. Each party was ordered to bear its own fees and costs. This outcome signals a negotiated resolution, preventing FibroGen from re-filing the same claims against these defendants.
Key Legal Issues
The absence of a public damages award or disclosed settlement amount is consistent with confidential resolution terms. While specific procedural milestones are not detailed, the 515-day litigation arc and the decision to dismiss with prejudice suggest the parties reached a mutual, bilateral resolution. Pharmaceutical patent infringement cases often turn on complex claim construction, validity challenges based on prior art, or inventorship disputes, especially when individual scientists are named as defendants, as in this case.
Freedom to Operate (FTO) Analysis for Indolizine Derivatives
This case highlights critical IP risks in small-molecule drug development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View related patent families in this technology space
- See which companies are most active in indolizine IP
- Understand chemical claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own chemical compounds or therapeutic products.
- Input your chemical structures or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Indolizine scaffolds in therapeutics
Key Patent Family
US11021478B2
Proactive FTO Essential
Before chemical synthesis and clinical trials
✅ Key Takeaways
Bilateral dismissal with prejudice and mutual cost-bearing strongly suggests a confidential settlement.
Search related case law →Naming individual scientist-defendants remains a viable pressure tactic in pharmaceutical patent cases, potentially expanding trade secret or inventorship angles.
Explore litigation strategies →Frequently Asked Questions
The case involved U.S. Patent No. US11021478B2 (Application No. US16/611838), directed to indolizine derivatives and their application in medicine.
The court entered dismissal pursuant to a Joint Stipulation filed by all parties, consistent with a negotiated resolution. Dismissal with prejudice prevents FibroGen from re-asserting the same claims against these defendants.
The patent remains valid and unadjudicated on the merits, preserving FibroGen’s ability to assert it against other parties. Companies developing indolizine-based therapeutics should conduct targeted FTO reviews against this patent family.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Case Locator – Case 3:22-cv-07148
- USPTO Patent Center – US11021478B2
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.